Sarthi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.50 Cr
as on 22-06-2024
- Paid Up Capital ₹ 3.55 Cr
as on 22-06-2024
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.40 Cr
as on 22-06-2024
- Revenue -82.41%
(FY 2019)
- Profit -64.01%
(FY 2019)
- Ebitda -65.56%
(FY 2019)
- Net Worth 0.10%
(FY 2019)
- Total Assets 0.29%
(FY 2019)
About Sarthi Pharmaceuticals
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.50 Cr and a paid-up capital of Rs 3.55 Cr.
The company has closed loans amounting to ₹1.40 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mayur Solanki, Mahesh Fulpadia, and Pareshkumar Sheth serve as directors at the Company.
- CIN/LLPIN
U24231GJ1995PLC024879
- Company No.
024879
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Mar 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sarthi Pharmaceuticals?
Board Members(3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Mayur Solanki | Director | 24-Feb-2014 | Current |
Mahesh Fulpadia | Director | 24-Feb-2014 | Current |
Pareshkumar Sheth | Director | 01-Dec-2005 | Current |
Financial Performance and Corporate Structure Insights of Sarthi Pharmaceuticals.
Sarthi Pharmaceuticals Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 82.41% decrease. The company also saw a substantial fall in profitability, with a 64.01% decrease in profit. The company's net worth moved up by a moderate rise of 0.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Sarthi Pharmaceuticals?
In 2021, Sarthi Pharmaceuticals had a promoter holding of 28.74% and a public holding of 71.26%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Merfin Shares And Stock Broking Private LimitedActive 20 years 6 months
Mayur Solanki is a mutual person
- Shreeji Business Trade Opportunity Private LimitedActive 4 years 11 months
Mayur Solanki is a mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
The Janta Co.Op.Bank Ltd. Creation Date: 16 Mar 2000 | ₹4.00 M | Satisfied |
The Janta Co-Op Bank Ltd Creation Date: 07 Apr 1999 | ₹4.00 M | Satisfied |
The Janta Co-Op Bank Ltd Creation Date: 07 Apr 1999 | ₹6.00 M | Satisfied |
How Many Employees Work at Sarthi Pharmaceuticals?
Unlock and access historical data on people associated with Sarthi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sarthi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sarthi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.